Nov 10, 2021 05:08 PM IST
Molnupiravir increases our armamentarium against COVID-19, but it cannot replace vaccines. So, then what’s the hype all about?
- Nov 08, 2021 07:16 PM IST
While Merck was the first to roll out its anti-COVID therapy, called molnupiravir, Pfizer has announced promising results of its own pill, called Paxlovid.
- Nov 05, 2021 04:58 PM IST
Currently all COVID-19 treatments used in the US require an IV or injection. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it.
- Oct 25, 2021 05:18 PM IST
The move, which could eventually lead to authorisation on the European market, comes two weeks after Merck applied for emergency use in the US of the anti-coronavirus drug.
- Oct 11, 2021 03:49 PM IST
Merck and its partner Ridgeback Biotherapeutic said they specifically asked the agency to grant emergency use for adults with mild-to-moderate COVID-19 who are at risk for severe disease or hospitalization. That is roughly the way COVID-19 infusion drugs are used.
- Oct 06, 2021 08:49 AM IST
Merck already has arrangements with eight Indian pharma companies to manufacture the drug and undoubtedly, all efforts will be made to make it more affordable than currently indicated
- Sep 30, 2021 07:34 PM IST
Merck executives told analysts Thursday they hope to launch the drug in either 2024 or 2025, and it has multi-billion dollar peak sales potential.
- May 17, 2021 02:29 PM IST
Swiss company Regeneron has signed with Cipla for exclusive distribution of its imported antibody cocktail in India.
- May 14, 2021 06:07 PM IST
Possibility of positive developments on the product pipeline front and restructuring initiatives can accelerate earnings growth for Lupin. We continue to believe this opportunity is more suitable for investors with high risk appetite and those who are ready to hold it long enough for the product pipeline to unfold
- May 14, 2021 11:03 AM IST
In the medium term, the focus is likely to be on the inhalation and biosimilar categories for Lupin, with scale-up in both US and European markets
- Mar 06, 2021 01:25 PM IST
"The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising," said William Fischer, Associate Professor of Medicine at the University of North Carolina School of Medicine, in a statement from the companies.
- Mar 02, 2021 07:14 PM IST
The announcement comes as the White House looks to speed the production of the single-dose vaccine.
- Feb 11, 2021 01:30 PM IST
Merck is now considering a range of options, both in the United States and around the world, mindful that anything it chooses to do would take months to bring to fruition, given the complexity of the manufacturing process
- Feb 04, 2021 08:13 PM IST
Frazier will continue to serve as executive chairman for Merck’s board of directors 'for a transition period to be determined by the board'.
- Jan 25, 2021 06:57 PM IST
Both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other COVID-19 vaccines, said Merck
- Dec 02, 2020 09:26 PM IST
Moderna is one of the front-runners in the race to develop a coronavirus vaccine, and on Monday filed for U.S. emergency use authorization of its vaccine.
- Sep 03, 2020 09:59 PM IST
Merck this year bought Austrian vaccine maker Themis Bioscience to gain its vaccine project that relies on a measles vector, and is also collaborating with research nonprofit IAVI on a second vaccine hopeful that uses the same technology as Merck’s Ebola vaccine ERVEBO.
- May 27, 2020 09:50 AM IST
It also announced a partnership with privately held Ridgeback Biotherapeutics to develop an experimental oral antiviral drug against COVID-19
- Dec 30, 2019 05:00 PM IST
The drug is now the only approved medicine in biomarker-selected patients with advanced pancreatic cancer.
- Jul 04, 2019 11:50 AM IST
- May 13, 2019 10:33 AM IST
- Feb 28, 2019 05:29 PM IST
Merck’s Rs440 a share special dividend is good news for investors but more so for its new parent P&G. After the dividend, life for investors will return to mundane things such as performance-driven valuations
- Oct 30, 2018 07:12 PM IST
The company had posted a net profit of Rs 31.68 crore for the corresponding period previous fiscal, Merck Ltd said in a BSE filing.
- Oct 10, 2018 10:28 PM IST
The Department of Pharmaceuticals has approved the proposal of Procter & Gamble Overseas India BV for acquisition of up to 77.80 percent of the paid-up equity share capital of the company, Merck Ltd said in a filing to BSE.
- Aug 08, 2018 12:00 PM IST
Merck has reported a sales total income from operations of Rs 220.29 crore and a net profit of Rs 48.31 crore for the quarter ended Jun-2018